Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lifted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Rating) by 68.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 141,025 shares of the company’s stock after purchasing an additional 57,121 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,061,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Comerica Bank increased its stake in shares of Teva Pharmaceutical Industries by 4.5% during the first quarter. Comerica Bank now owns 50,689 shares of the company’s stock worth $491,000 after buying an additional 2,177 shares during the period. State of New Jersey Common Pension Fund D increased its stake in shares of Teva Pharmaceutical Industries by 9.5% during the first quarter. State of New Jersey Common Pension Fund D now owns 645,414 shares of the company’s stock worth $6,060,000 after buying an additional 55,900 shares during the period. abrdn plc increased its stake in Teva Pharmaceutical Industries by 18.8% in the first quarter. abrdn plc now owns 104,263 shares of the company’s stock valued at $978,000 after purchasing an additional 16,493 shares during the last quarter. Gladstone Institutional Advisory LLC purchased a new position in Teva Pharmaceutical Industries in the first quarter valued at approximately $138,000. Finally, Victory Capital Management Inc. increased its stake in Teva Pharmaceutical Industries by 41.8% in the first quarter. Victory Capital Management Inc. now owns 185,054 shares of the company’s stock valued at $1,612,000 after purchasing an additional 54,505 shares during the last quarter. Institutional investors and hedge funds own 46.22% of the company’s stock.

Wall Street Analyst Weigh In

TEVA has been the topic of several recent analyst reports. UBS Group lowered shares of Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating in a research note on Friday, November 4th. Jefferies Financial Group reiterated a “buy” rating and issued a $10.00 price target on shares of Teva Pharmaceutical Industries in a research note on Friday, October 21st. Piper Sandler dropped their price target on shares of Teva Pharmaceutical Industries from $8.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday. Bank of America upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and raised their target price for the stock from $10.00 to $13.00 in a research report on Friday, August 5th. Finally, BMO Capital Markets decreased their price target on Teva Pharmaceutical Industries from $11.00 to $10.00 and set a “market perform” rating for the company in a report on Monday, November 7th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $10.44.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $8.80 on Thursday. Teva Pharmaceutical Industries Limited has a one year low of $6.78 and a one year high of $11.34. The company has a debt-to-equity ratio of 1.94, a quick ratio of 0.66 and a current ratio of 0.99. The business has a fifty day moving average of $8.54 and a two-hundred day moving average of $8.63. The company has a market cap of $9.77 billion, a P/E ratio of -7.59 and a beta of 1.27.

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) last released its quarterly earnings results on Thursday, November 3rd. The company reported $0.56 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by ($0.02). The firm had revenue of $3.60 billion for the quarter, compared to analyst estimates of $3.86 billion. Teva Pharmaceutical Industries had a positive return on equity of 26.97% and a negative net margin of 8.52%. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.42 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

(Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

See Also

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Rating).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.